▎Edited by the WuXi AppTec content team

The NanoGalaxy platform encompasses a wide array of chemically diverse hydrophilic nanoparticles (HNPs), each with unique properties suited for targeting different tissues and cell types, while also capable of carrying various types of genetic drugs.（genetic medicine）Payload.GenEdit has successfully delivered siRNA, mRNA, and gene editing systems targeting the nervous system, immune system, and other extrahepatic systems in vivo. The company is actively advancing research in multiple therapeutic areas through internal development and collaborative projects.

According to the agreement, GenEdit will collaborate with Genentech to jointly develop hydrophilic nanoparticles for the creation of nucleic acid-based drugs targeting autoimmune diseases. Genentech will be responsible for the preclinical, clinical, regulatory development, and eventual commercialization of products based on GenEdit's nanoparticle technology.

▲GKunwoo Lee, Ph.D., CEO of enEdit

Kunwoo Lee, Ph.D., CEO of GenEdit, in an interview with the WuXi AppTec content teamInterviewProfessor Jennifer Doudna and other gene-editing pioneers have previously stated that the three challenges for in vivo gene drugs are delivery, delivery, and delivery. New technologies such as gene therapy, gene silencing, and gene editing hold tremendous promise. However, they can only be effective when they reach the affected tissues and cells, and current delivery options are limited.The main requirements for new delivery technologies are tissue selectivity, payload flexibility, the ability to re-dose, and manufacturing convenience. Combining all these attributes into one platform will truly enable gene therapies to reach their full potential.

Everyone is watching

As a CTDMO under WuXi AppTec that focuses on cell and gene therapies, WuXi ATU is committed to accelerating and transforming the development, testing, manufacturing, and commercialization of gene and cell therapies as well as other advanced therapies. WuXi ATU can help global customers bring more innovative therapies to market sooner, benefiting patients. If you have related business needs, please click on the image below to fill in the specific information.

▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接platform and fill in your business needs information.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

Copyright Statement: This article is from the WuXi AppTec content team. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.